

AGC Biologics Secures Long-Term Strategic Manufacturing Agreement with a Leading Global Biopharmaceutical Company

— Yokohama Site Progressing Steadily Toward Commercial Manufacturing in 2027 —

Tokyo, July 28, 2026— AGC Biologics, Inc., a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO ^{*1}) and a subsidiary of AGC Inc. (Tokyo; President: Yoshinori Hirai), has entered into a long-term manufacturing agreement with a leading global biopharmaceutical company for the development and manufacturing of biopharmaceutical products.

Under this agreement, AGC Biologics has been selected as a long-term strategic manufacturing partner supporting the global supply of multiple biopharmaceutical products developed by the customer. Total revenue generated under the agreement is expected to reach several tens of billions of yen over the contract term. This selection reflects AGC Biologics' proven global track record, the trust it has earned from customers, and the state-of-the-art facilities and advanced technologies of its new biopharmaceutical CDMO site currently under development in Yokohama, Japan (the "Yokohama Site").

AGC Biologics Yokohama Site



The Yokohama Site is being developed as a manufacturing hub capable of supporting three modalities: mammalian cell-derived biologics, mRNA therapeutics, and cell therapies. The site will feature one of the largest mammalian cell culture capacities among CDMO facilities in Japan. ^{*2} Under this agreement, AGC Biologics will provide commercial manufacturing services for biopharmaceutical products utilizing this capacity. This agreement reflects the steady progress being made toward the launch of GMP^{*3}-compliant services at the Yokohama Site in 2027. Through the establishment of the Yokohama Site, AGC Biologics will expand its global network across Japan, the United States, and Europe, contributing to the stable supply of biopharmaceutical products for customers worldwide.

Under its medium-term management plan, [**AGC plus-2026**](#), the AGC Group has identified three social values it aims to create through its products and technologies. One of these values, "Well-being" focuses on contributing to safe, secure, and healthy lives through the stable supply of products and services essential to

<Media inquiries>

AGC Inc.

Corporate Communications & Investor Relations Division

[Contact form](#)

healthcare and everyday life. Through CDMO services supporting a wide range of modalities, including biopharmaceuticals, the Life Science business supports customers from early-stage development through commercial production and contributes to improving the health and well-being of people around the world.

<Notes>

*¹ CDMO: Contract Development and Manufacturing Organization

*² Based on AGC estimates

*³ GMP (Good Manufacturing Practice): Standards for the manufacturing and quality control of pharmaceuticals.

<Reference Information>

About the AGC Group

AGC Inc. is a global materials company operating across a wide range of products and industries. Founded in 1907 with flat glass production as its original business, AGC has expanded its operations in line with changing societal needs, providing materials and solutions based on its core material and production technologies. Today, the AGC Group operates in more than 30 countries and regions, with businesses spanning glass, electronics, chemicals, life science, and ceramics. Guided by its purpose, “AGC, an everyday essential part of our world,” the Group provides value to society through the pursuit of innovation. For more information, visit www.agc.com/en.

<Media inquiries>

AGC Inc.

Corporate Communications & Investor Relations Division

[Contact form](#)